Clofazimine broadly inhibits coronaviruses including SARS-CoV-2

• Published in: Nature (London) Vol. 593; no. 7859; pp. 418 - 423
• Main Authors: Yuan, Shuofeng, Yin, Xin, Meng, Xiangzhi, Chan, Jasper Fuk-Woo, Ye, Zi-Wei, Riva, Laura, Pache, Lars, Chan, Chris Chun-Yiu, Lai, Pok-Man, Chan, Chris Chung-Sing, Poon, Vincent Kwok-Man, Lee, Andrew Chak-Yiu, Matsunaga, Naoko, Pu, Yuan, Yuen, Chun-Kit, Cao, Jianli, Liang, Ronghui, Tang, Kaiming, Sheng, Li, Du, Yushen, Xu, Wan, Lau, Chit-Ying, Sit, Ko-Yung, Au, Wing-Kuk, Wang, Runming, Zhang, Yu-Yuan, Tang, Yan-Dong, Clausen, Thomas Mandel, Pihl, Jessica, Oh, Juntaek, Sze, Kong-Hung, Zhang, Anna Jinxia, Chu, Hin, Kok, Kin-Hang, Wang, Dong, Cai, Xue-Hui, Esko, Jeffrey D., Hung, Ivan Fan-Ngai, Li, Ronald Adolphus, Chen, Honglin, Sun, Hongzhe, Jin, Dong-Yan, Sun, Ren, Chanda, Sumit K., Yuen, Kwok-Yung
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 20.05.2021; Nature Publishing Group
• Subjects: 13; 13/1; 13/21; 38/39; 631/250/255/2514; 631/326/596/1296; 631/326/596/4130; 64; Adenosine Monophosphate - analogs & derivatives; Adenosine Monophosphate - pharmacology; Adenosine Monophosphate - therapeutic use; Alanine - analogs & derivatives; Alanine - pharmacology; Alanine - therapeutic use; Animals; Anti-Inflammatory Agents - pharmacokinetics; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Antiviral Agents - pharmacokinetics; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Antiviral drugs; Bioavailability; Biological Availability; Cell Fusion; Cell Line; Clofazimine; Clofazimine - pharmacokinetics; Clofazimine - pharmacology; Clofazimine - therapeutic use; Coronaviridae; Coronavirus - classification; Coronavirus - drug effects; Coronavirus - growth & development; Coronavirus - pathogenicity; Coronaviruses; COVID-19; Cricetinae; DNA helicase; DNA Helicases - antagonists & inhibitors; Dosage and administration; Drug Synergism; Female; Glycoproteins; Health services; Humanities and Social Sciences; Humans; Inflammation; Leprosy; Life Cycle Stages - drug effects; Male; Mesocricetus; Middle East respiratory syndrome; Mortality; multidisciplinary; Pandemics; Pathogenesis; Pre-Exposure Prophylaxis; Respiratory diseases; Respiratory tract; SARS-CoV-2 - drug effects; SARS-CoV-2 - growth & development; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Species Specificity; Spike glycoprotein; Spike Glycoprotein, Coronavirus - antagonists & inhibitors; Transcription, Genetic - drug effects; Transcription, Genetic - genetics; Viral diseases; Zoonoses; China; United States > US

The COVID-19 pandemic is the third outbreak this century of a zoonotic disease caused by a coronavirus, following the emergence of severe acute respiratory syndrome (SARS) in 2003 1 and Middle East respiratory syndrome (MERS) in 2012 2 . Treatment options for coronaviruses are limited. Here we show...